Evidence map›Paper›PMID 39610907›Full record

ArticleJournal of medical cases2024

New Onset of Type 1 Diabetes Mellitus Post-COVID-19 Vaccine.

Khaled H Aburisheh, Hamza M K Enabi, Nora A Alodah, Bassam H Alotary, Linah A Algheryafi, Ayman M Almairi, Amani A Aldhewaila

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical cases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Khaled H AburishehUniversity Diabetes Center, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0001-9528-6993
Hamza M K EnabiAlfaisal University, Riyadh, Saudi Arabia.
Nora A AlodahAlfaisal University, Riyadh, Saudi Arabia.
Bassam H AlotaryAlfaisal University, Riyadh, Saudi Arabia.
Linah A AlgheryafiAlfaisal University, Riyadh, Saudi Arabia.
Ayman M AlmairiAlfaisal University, Riyadh, Saudi Arabia.
Amani A AldhewailaUniversity Diabetes Center, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with an increased morbidity and mortality worldwide. Coronavirus disease 2019 (COVID-19) vaccines have shown high efficacy in preventing the infection but with many possible side effects such as hyperglycemia. New-onset diabetes mellitus (DM) and severe metabolic complications have been reported post-vaccination. Here we report a 45-year-old woman who came to the hospital complaining of polyurea, polydipsia, and weight loss 3 weeks after the first activation dose of COVID-19 vaccine. Her hemoglobin A1c (HbA1c) upon presentation was 9% without any prior history of DM. She was diagnosed with type 1 diabetes mellitus (T1DM), as the anti-glutamic acid decarboxylase (GAD) antibody was positive and complicated during follow-up with diabetic ketoacidosis (DKA). This is the first case in Saudi Arabia suggesting that the COVID-19 RNA-based vaccines might cause new onset of T1DM, complicated by late DKA.

Indexed as

COVID-19HyperglycemiamRNA vaccineSARS-CoV-2Type 1 diabetes mellitus

Identifiers

PMID39610907
PMCPMC11602176

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.